Print
Print
Leah SherwoodChronic Myeloid Leukemia | November 23, 2022
Jorge Cortes, MD, discusses the financial toxicity of FDA-approved drugs for malignant hematology and OPTIC trial results.
Read More
Leah SherwoodAcute Lymphoblastic Leukemia | November 23, 2022
Nicholas J. Short, MD, speaks about how novel chemotherapy can eliminate the need for transplant in ALL.
Leah LawrencePrint | November 23, 2022
A deeper understanding of ALL has led to more targeted approaches and personalized treatments for this patient population.
Cecilia BrownPrint | November 23, 2022
Eprenetapopt and azacitidine after allogeneic HSCT was well tolerated in patients with TP53-mutated AML and MDS.
Leah SherwoodPrint | November 23, 2022
Manali Kamdar, MD; and Craig S. Sauter, MD, FACP; debate CAR T-cell therapy and AHSCT in second-line DLBCL.
Cecilia BrownPrint | November 23, 2022
Baseline genetic characteristics are the primary determinants of allogeneic HSCT outcomes in older adults with AML.
Leah SherwoodPrint | November 23, 2022
Secondary central nervous system lymphoma (SCNSL) refers to lymphoma within the CNS that originated outside the CNS.
Leah SherwoodPrint | November 23, 2022
A Biologics License Application was submitted to the FDA by the manufacturer of the drug denileukin diftitox.
Leah SherwoodAggressive B-Cell Lymphoma | November 23, 2022
The ​European Medicines Agency recommended Marketing Authorization of loncastuximab tesirine for relapsed/refractory DLBCL.
Leah SherwoodMarginal Zone Lymphoma | November 23, 2022
The European Medicines Agency issued a positive opinion recommending approval of zanubrutinib in adults with MZL.
Leah SherwoodPrint | November 23, 2022
Courtney D. DiNardo, MD, MSCE, talks about mentorship and her research on hereditary cancer predisposition syndromes.
Jerald Radich, MDViewpoints | November 23, 2022
Jerald Radich, MD; and Christopher S. Hourigan, MD, DPhil, FACP, FRCP; discuss minimal residual disease.
Cecilia BrownPrint | October 13, 2022
The FDA approved ibrutinib for pediatric patients aged one year and older who have chronic GHVD after failure of at least one ...
Cecilia BrownPrint | October 13, 2022
The FDA has approved pemigatinib for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) ...
Kerri FitzgeraldPrint | September 13, 2022
Because WM is considered incurable, an important treatment consideration is optimization of quality of life.
Kerri FitzgeraldPrint | September 13, 2022
In his President's Letter, Moshe Talpaz, MD, discusses all of the treatment progress made for hematologic malignancies.
Kerri FitzgeraldChronic Lymphocytic Leukemia | September 13, 2022
President-Elect Jennifer R. Brown, MD, PhD, will take office during the 10th Annual SOHO Conference. Dr. Brown spoke with ...
Kerri FitzgeraldPrint | September 13, 2022
Dr. Pro discusses the exciting advancements made in lymphoma and what still needs to be done to improve patient outcomes.
Cecilia BrownMyelodysplastic Syndromes | September 13, 2022
Alexandre Bazinet, MD, and colleagues conducted the single-center, dose-expansion phase I/II trial...
Cecilia BrownMyelodysplastic Syndromes | September 13, 2022
It led to an overall response rate of 74% in patients with newly diagnosed IDH2-mutated myelodysplastic syndrome.
Advertisement
Editorial Board

Advertisement